PPARδ has been shown to inhibit non-melanoma skin cancer by enhancing KC terminal differentiation and senescence, blocking KCs in the G2/M phase of the cell cycle, and inhibiting endoplasmic reticulum stress and specific inflammatory pathways [111,112,113]. Here, TBCE is linked to non-melanoma skin carcinoma.